Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1534 - CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent


09 Oct 2016


Poster display


Ronald de Wit


Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372


R. de Wit1, K. Fizazi2, E. Efstathiou3, R. Dittamore4, S. Hitier5, K. Pantel6, C. Sternberg7, B.F. Tombal8, C. Wülfing9, J. de Bono10

Author affiliations

  • 1 Medical Oncology, Erasmus University Medical Center, 3075EA - Rotterdam/NL
  • 2 Department Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 3 Gu Medical Oncology  , md anderson cancer center  , 77030   - Houston/US
  • 4 Translational Research, Epic Sciences Inc., 92121 - San Diego/US
  • 5 75, Sanofi, 75008 Paris - Paris/FR
  • 6 Tumor Biology, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, 20246 - Hamburg/DE
  • 7 Oncology, San Camillo–Forlanini Hospital, 00152 - Rome/IT
  • 8 Urology, Cliniques Universitaires St. Luc, 12000 - Brussels/BE
  • 9 Urology, Asklepios Klinik Altona, 22763 - Hamburg/DE
  • 10 Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB


Abstract 1534


mCRPC is highly heterogeneous with coexistence of AR-dependent and AR-independent tumor clones. New AR-targeted agents (abiraterone acetate, enzalutamide) and taxanes (docetaxel (DOC), cabazitaxel - specifically developed to overcome DOC resistance) are the backbone of mCRPC therapy. The rising concern of cross-resistance between mCRPC therapies and the evidence that some patients may not respond to all available drugs have increased the complexity of managing mCRPC. There is thus a need to design trials helping to define the optimal sequence of therapies to optimize patient outcomes.

Trial design

CARD is a randomized phase 4 trial involving 79 sites in 12 European countries. A total of 324 patients with mCRPC previously treated with DOC and who failed a prior AR-targeted agent (abiraterone acetate or enzalutamide, either before or after DOC) within 12 months of AR-targeted treatment initiation will be randomized (1:1) to receive cabazitaxel (25mg/m2 every 3 weeks plus daily prednisone and prophylactic G-CSF) or the alternative AR-targeted agent until radiographic progression, unacceptable toxicity or patient's request. Randomization will be stratified by ECOG performance status (0-1 vs. 2), time to progression with prior AR-targeted agent (

Clinical trial identification


Legal entity responsible for the study





R. de Wit: Research grant from Sanofi International coordinator of CARD study Consulting fees from Sanofi.

R. de Wit: Research grant from Sanofi. Consulting fee from Sanofi CARD investigator and Steering committee member.

K. Fizazi: Paid advisor at Sanofi advisory boards Investigator and steering committee member for CARD study.

E. Efstathiou: Research grant from Sanofi. Paid advisor at Sanof advisory boards. Investigator and steering Committee member of CARD study.

R. Dittamore: Employee of Epic Sciences, Inc., La Jolla, USA.

S. Hitier: CARD statistician - Employee of Sanofi.

K. Pantel: Member of CARD translational steering committee.

C. Sternberg: Investigator and steering committee member of CARD study. Consulting fee from Sanofi

B. Tombal: Paid advisor by Sanofi Investigator and Steering Committee member of CARD study.

C. Wülfing: Investigator and steering committee member of CARD study.

J. de Bono: Johann de Bono served on Sanofi advisory boards as a paid advisor. He is also investigator and member of CARD Steering committee.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings